The short answer
The NHS New Medicine Service (NMS) is a community pharmacy service for people who have just started a medicine for a long-term condition. Over two conversations in the first few weeks, a pharmacist checks how the patient is getting on: whether they’re taking it, any side effects, and any worries. Problems the pharmacist can’t sort out with the patient go back to the prescriber or the PCN clinical pharmacist.
It’s meant to add to what the prescriber, the PCN clinical pharmacist or the practice team has already told the patient, not to replace it. Its aims include better adherence, less wasted medicine, spotting side effects early and fewer avoidable admissions.
Which patients qualify
Patients newly prescribed a medicine on the NMS eligible drug list for one of these 18 conditions:
- Acute Coronary Syndromes
- Asthma
- Atrial Fibrillation
- Chronic Obstructive Pulmonary Disease (COPD)
- Coronary Heart Disease
- Depression (adults aged 18 and over)
- Type 2 Diabetes
- Epilepsy
- Glaucoma
- Gout
- Heart Failure
- Hypercholesterolaemia
- Hypertension
- Long-term risk of venous thromboembolism or embolism
- Osteoporosis
- Parkinson's Disease
- Stroke or transient ischaemic attack (TIA)
- Urinary incontinence or retention
A few rules decide whether a particular prescription counts:
- First prescription only. The service is for the first time a patient is prescribed an individual medicine.
- Not a higher strength of a medicine the patient already takes, and not a medicine restarted after it was stopped.
- A combination product counts as a different medicine, so moving to one can qualify.
- A change of formulation usually doesn’t qualify. The pharmacist can still offer it where the patient clearly benefits, for example a new inhaler device, and records why.
- Depression is included for adults aged 18 and over only.
The patient, or a carer, parent or guardian where they can’t consent themselves, gives verbal consent, which includes sharing information with the GP practice if needed.
How the three stages work
- Engagement. The patient is recruited when the new medicine is dispensed, or arrives signposted by their practice or referred from hospital. They get information about the service and a time for the next conversation.
- Intervention, 7 to 14 days later. The pharmacist goes through how the medicine is going, using the national NMS interview schedule, and agrees what to do about any problems.
- Follow-up, 14 to 21 days after that. The pharmacist checks again, and the service ends.
Consultations can be in the pharmacy’s consultation room, by telephone or by live video, where the pharmacist judges that clinically appropriate. Only a pharmacist can carry them out. If the patient can’t be reached after a further try, the service ends.
What it means for GP practices
- Signposting at the point of prescribing. General practice is one of the routes into the service. Telling a patient starting, say, an anticoagulant for Atrial Fibrillation or a statin that their pharmacy can check in with them in the next few weeks makes it more likely they take it up.
- Feedback coming back. When a pharmacist finds something the prescriber needs to act on (an interaction, a side effect, the medicine not working), it comes back to the practice through the locally agreed route, which may be the NMS GP feedback form. Agree with your local pharmacies how those arrive and who in the practice picks them up.
- Patients not registered with a GP are told how to register, and the pharmacist tries to get clinically relevant information to whoever prescribed.
Where PCN clinical pharmacists come in
The service specification names the PCN clinical pharmacist alongside the prescriber as someone a community pharmacist can refer a problem to. In practice that makes NMS feedback natural work for the practice’s clinical pharmacist: reviewing what the community pharmacist found, changing or stopping the medicine where needed, and making sure the patient hears back.
It also connects to the rest of their work. A pharmacist doing structured medication reviews or long-term condition reviews often starts new medicines, and can signpost each of those patients to the service at the time.
We place clinical pharmacists with GP practices and PCNs, funded through ARRS, and every session is logged in ReportRx so you can see where the time goes. Book a call to talk through what would help your practices.
After a hospital stay
Hospitals can refer patients into the service, including through the Discharge Medicines Service. If the hospital has already supplied the new medicine, the community pharmacy doesn’t need to have dispensed the first prescription itself.
Questions people ask
Who provides the New Medicine Service?
Community pharmacies that have told their ICB they provide it. Only a pharmacist can carry out the consultations.
Can a GP practice refer a patient to the New Medicine Service?
General practice can signpost patients to it. The patient then takes their first prescription for the new medicine to a pharmacy that provides the service.
Does a higher dose of the same medicine count?
No. The service is only for the first time a patient is prescribed an individual medicine, so a higher strength of something they already take doesn't qualify, and nor does restarting a medicine they had stopped.
Can the consultations be by phone?
Yes. They can be face to face, by telephone or by live video, where the pharmacist judges that clinically appropriate. Text messages can support a consultation but can't replace it.
What happens if the pharmacist finds a problem?
If the prescriber or the PCN clinical pharmacist needs to act, the pharmacist explains this to the patient and refers it to them through the locally agreed route, which may be the NMS GP feedback form.
Is the New Medicine Service the same as a structured medication review?
No. The New Medicine Service is a community pharmacy service for people starting a new medicine. Structured medication reviews are carried out in general practice, often by PCN clinical pharmacists, for people with more complex medicines.